Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.91
GILD's Cash to Debt is ranked lower than
80% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. GILD: 0.91 )
Ranked among companies with meaningful Cash to Debt only.
GILD' s 10-Year Cash to Debt Range
Min: 0.15  Med: 1.74 Max: N/A
Current: 0.91
Equity to Asset 0.45
GILD's Equity to Asset is ranked lower than
74% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. GILD: 0.45 )
Ranked among companies with meaningful Equity to Asset only.
GILD' s 10-Year Equity to Asset Range
Min: 0.21  Med: 0.61 Max: 0.95
Current: 0.45
0.21
0.95
Interest Coverage 37.05
GILD's Interest Coverage is ranked lower than
85% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GILD: 37.05 )
Ranked among companies with meaningful Interest Coverage only.
GILD' s 10-Year Interest Coverage Range
Min: 5.85  Med: 37.05 Max: 2509.2
Current: 37.05
5.85
2509.2
F-Score: 8
Z-Score: 8.02
M-Score: -2.26
WACC vs ROIC
8.73%
84.39%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 64.01
GILD's Operating margin (%) is ranked higher than
97% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -71.01 vs. GILD: 64.01 )
Ranked among companies with meaningful Operating margin (%) only.
GILD' s 10-Year Operating margin (%) Range
Min: -1185.19  Med: 28.87 Max: 61.33
Current: 64.01
-1185.19
61.33
Net-margin (%) 51.69
GILD's Net-margin (%) is ranked higher than
95% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. GILD: 51.69 )
Ranked among companies with meaningful Net-margin (%) only.
GILD' s 10-Year Net-margin (%) Range
Min: -1014.81  Med: 24.54 Max: 48.62
Current: 51.69
-1014.81
48.62
ROE (%) 93.90
GILD's ROE (%) is ranked higher than
99% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -30.92 vs. GILD: 93.90 )
Ranked among companies with meaningful ROE (%) only.
GILD' s 10-Year ROE (%) Range
Min: -49.14  Med: 29.75 Max: 90.32
Current: 93.9
-49.14
90.32
ROA (%) 44.09
GILD's ROA (%) is ranked higher than
98% of the 848 Companies
in the Global Biotechnology industry.

( Industry Median: -26.61 vs. GILD: 44.09 )
Ranked among companies with meaningful ROA (%) only.
GILD' s 10-Year ROA (%) Range
Min: -30.31  Med: 13.45 Max: 42.28
Current: 44.09
-30.31
42.28
ROC (Joel Greenblatt) (%) 492.79
GILD's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 819 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. GILD: 492.79 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GILD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -71.55  Med: 116.77 Max: 484.47
Current: 492.79
-71.55
484.47
Revenue Growth (3Y)(%) 41.70
GILD's Revenue Growth (3Y)(%) is ranked higher than
89% of the 402 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. GILD: 41.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GILD' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 32.60 Max: 71.8
Current: 41.7
0
71.8
EBITDA Growth (3Y)(%) 55.60
GILD's EBITDA Growth (3Y)(%) is ranked higher than
93% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. GILD: 55.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GILD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -20.6  Med: 30.15 Max: 119
Current: 55.6
-20.6
119
EPS Growth (3Y)(%) 60.70
GILD's EPS Growth (3Y)(%) is ranked higher than
95% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. GILD: 60.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GILD' s 10-Year EPS Growth (3Y)(%) Range
Min: -20.6  Med: 29.65 Max: 153.3
Current: 60.7
-20.6
153.3
» GILD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

GILD Guru Trades in Q2 2014

Joel Greenblatt 466,853 sh (New)
Alan Fournier 2,070,000 sh (New)
Ken Heebner 1,710,000 sh (New)
Ken Fisher 975,483 sh (+62.11%)
John Rogers 638,734 sh (+60.78%)
Ray Dalio 349,821 sh (+41.22%)
Julian Robertson 443,911 sh (+28.55%)
Pioneer Investments 3,899,022 sh (+16.40%)
Mario Gabelli 49,170 sh (+11.14%)
RS Investment Management 192,614 sh (+6.88%)
John Burbank 3,774 sh (+4.28%)
First Eagle Investment 400 sh (unchged)
Caxton Associates 100,000 sh (unchged)
George Soros Sold Out
David Rolfe Sold Out
Caxton Associates Sold Out
Louis Moore Bacon Sold Out
Jim Simons 166,648 sh (-11.99%)
Paul Tudor Jones 9,304 sh (-13.89%)
Ronald Muhlenkamp 144,715 sh (-24.63%)
Mariko Gordon 11,654 sh (-35.57%)
Vanguard Health Care Fund 1,633,700 sh (-39.79%)
Jeremy Grantham 10,600 sh (-97.95%)
» More
Q3 2014

GILD Guru Trades in Q3 2014

David Dreman 2,388 sh (New)
Louis Moore Bacon 11,734 sh (New)
Stanley Druckenmiller 217,500 sh (New)
Dodge & Cox 4,800 sh (New)
Paul Tudor Jones 30,245 sh (+225.08%)
John Burbank 12,073 sh (+219.90%)
Ronald Muhlenkamp 206,350 sh (+42.59%)
Joel Greenblatt 664,223 sh (+42.28%)
John Rogers 643,896 sh (+0.81%)
First Eagle Investment 400 sh (unchged)
Pioneer Investments 3,536,065 sh (unchged)
Julian Robertson 443,911 sh (unchged)
Jim Simons Sold Out
Ken Heebner 1,560,000 sh (-8.77%)
Alan Fournier 1,861,000 sh (-10.10%)
Mariko Gordon 10,366 sh (-11.05%)
Mario Gabelli 42,600 sh (-13.36%)
RS Investment Management 151,879 sh (-21.15%)
Ken Fisher 763,423 sh (-21.74%)
Ray Dalio 241,521 sh (-30.96%)
Jeremy Grantham 6,700 sh (-36.79%)
Vanguard Health Care Fund 379,200 sh (-76.79%)
» More
Q4 2014

GILD Guru Trades in Q4 2014

Steven Cohen 1,061,100 sh (New)
Leon Cooperman 612,500 sh (New)
Jim Simons 941,400 sh (New)
First Eagle Investment 1,315,088 sh (+328672.00%)
Paul Tudor Jones 109,372 sh (+261.62%)
John Burbank 37,750 sh (+212.68%)
Ray Dalio 537,321 sh (+122.47%)
Joel Greenblatt 1,009,462 sh (+51.98%)
RS Investment Management 190,460 sh (+25.40%)
John Rogers 802,803 sh (+24.68%)
Julian Robertson 533,911 sh (+20.27%)
Alan Fournier 2,141,000 sh (+15.05%)
Ronald Muhlenkamp 218,945 sh (+6.10%)
Ken Fisher 771,501 sh (+1.06%)
First Eagle Investment 1,200 sh (unchged)
Louis Moore Bacon 50,000 sh (unchged)
Mario Gabelli 42,600 sh (unchged)
Vanguard Health Care Fund Sold Out
David Dreman Sold Out
Louis Moore Bacon Sold Out
Ken Heebner Sold Out
Stanley Druckenmiller Sold Out
Mariko Gordon Sold Out
Dodge & Cox 4,510 sh (-6.04%)
Pioneer Investments 3,180,990 sh (-10.04%)
Jeremy Grantham 4,600 sh (-31.34%)
» More
Q1 2015

GILD Guru Trades in Q1 2015

Lee Ainslie 2,650 sh (New)
NWQ Managers 113,100 sh (New)
Murray Stahl 8,700 sh (New)
John Buckingham 45,281 sh (New)
Louis Moore Bacon 44,389 sh (New)
David Dreman 5,580 sh (New)
Jim Simons 4,032,048 sh (+328.30%)
John Burbank 45,652 sh (+20.93%)
Mario Gabelli 49,470 sh (+16.13%)
John Rogers 891,645 sh (+11.07%)
Joel Greenblatt 1,107,732 sh (+9.73%)
Steven Cohen 1,158,000 sh (+9.13%)
Ken Fisher 789,615 sh (+2.35%)
Jeremy Grantham 4,600 sh (unchged)
NWQ Managers 55,200 sh (unchged)
Alan Fournier Sold Out
Leon Cooperman Sold Out
Ronald Muhlenkamp 218,740 sh (-0.09%)
Pioneer Investments 3,046,688 sh (-4.22%)
Dodge & Cox 4,250 sh (-5.76%)
RS Investment Management 144,820 sh (-23.96%)
Julian Robertson 231,511 sh (-56.64%)
Paul Tudor Jones 6,535 sh (-94.02%)
Ray Dalio 25,221 sh (-95.31%)
First Eagle Investment 400 sh (-99.97%)
» More
» Details

Insider Trades

Latest Guru Trades with GILD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Gilead Sciences Inc

Alan Fournier Sells Stake in Gilead Sciences
Guru Alan Fournier (Trades, Portfolio) has been investing for more than a quarter of a century. Today he manages Pennant Master Fund, Pennant Windward Master Fund, Broadway Gate Master Fund, Ltd., and Pennant General Partner, LLC. Perhaps understandably, his personal investments have been modest compared to many of the gurus we follow, but in the first quarter of 2015, they were significant, as they usually are. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 13.10
GILD's P/E(ttm) is ranked higher than
88% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 40.90 vs. GILD: 13.10 )
Ranked among companies with meaningful P/E(ttm) only.
GILD' s 10-Year P/E(ttm) Range
Min: 9.69  Med: 22.72 Max: 45.41
Current: 13.1
9.69
45.41
Forward P/E 9.79
GILD's Forward P/E is ranked higher than
89% of the 158 Companies
in the Global Biotechnology industry.

( Industry Median: 23.87 vs. GILD: 9.79 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 13.10
GILD's PE(NRI) is ranked higher than
89% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 39.90 vs. GILD: 13.10 )
Ranked among companies with meaningful PE(NRI) only.
GILD' s 10-Year PE(NRI) Range
Min: 9.68  Med: 22.65 Max: 45.49
Current: 13.1
9.68
45.49
P/B 9.89
GILD's P/B is ranked lower than
77% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: 4.68 vs. GILD: 9.89 )
Ranked among companies with meaningful P/B only.
GILD' s 10-Year P/B Range
Min: 4.16  Med: 8.39 Max: 18.59
Current: 9.89
4.16
18.59
P/S 6.76
GILD's P/S is ranked higher than
65% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.51 vs. GILD: 6.76 )
Ranked among companies with meaningful P/S only.
GILD' s 10-Year P/S Range
Min: 3.48  Med: 8.68 Max: 14.41
Current: 6.76
3.48
14.41
PFCF 11.30
GILD's PFCF is ranked higher than
86% of the 142 Companies
in the Global Biotechnology industry.

( Industry Median: 41.97 vs. GILD: 11.30 )
Ranked among companies with meaningful PFCF only.
GILD' s 10-Year PFCF Range
Min: 8.33  Med: 23.09 Max: 59.09
Current: 11.3
8.33
59.09
POCF 10.96
GILD's POCF is ranked higher than
88% of the 201 Companies
in the Global Biotechnology industry.

( Industry Median: 34.67 vs. GILD: 10.96 )
Ranked among companies with meaningful POCF only.
GILD' s 10-Year POCF Range
Min: 8.01  Med: 21.33 Max: 52.27
Current: 10.96
8.01
52.27
EV-to-EBIT 9.67
GILD's EV-to-EBIT is ranked higher than
83% of the 223 Companies
in the Global Biotechnology industry.

( Industry Median: 30.72 vs. GILD: 9.67 )
Ranked among companies with meaningful EV-to-EBIT only.
GILD' s 10-Year EV-to-EBIT Range
Min: -103.9  Med: 15.85 Max: 473.4
Current: 9.67
-103.9
473.4
PEG 0.48
GILD's PEG is ranked higher than
95% of the 73 Companies
in the Global Biotechnology industry.

( Industry Median: 2.75 vs. GILD: 0.48 )
Ranked among companies with meaningful PEG only.
GILD' s 10-Year PEG Range
Min: 0.36  Med: 1.33 Max: 4.23
Current: 0.48
0.36
4.23
Shiller P/E 37.22
GILD's Shiller P/E is ranked higher than
66% of the 108 Companies
in the Global Biotechnology industry.

( Industry Median: 48.44 vs. GILD: 37.22 )
Ranked among companies with meaningful Shiller P/E only.
GILD' s 10-Year Shiller P/E Range
Min: 17.87  Med: 45.51 Max: 1840.8
Current: 37.22
17.87
1840.8
Current Ratio 2.70
GILD's Current Ratio is ranked lower than
66% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.38 vs. GILD: 2.70 )
Ranked among companies with meaningful Current Ratio only.
GILD' s 10-Year Current Ratio Range
Min: 1.09  Med: 6.88 Max: 20.42
Current: 2.7
1.09
20.42
Quick Ratio 2.44
GILD's Quick Ratio is ranked lower than
65% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. GILD: 2.44 )
Ranked among companies with meaningful Quick Ratio only.
GILD' s 10-Year Quick Ratio Range
Min: 0.83  Med: 6.32 Max: 20.42
Current: 2.44
0.83
20.42
Days Inventory 178.16
GILD's Days Inventory is ranked lower than
69% of the 402 Companies
in the Global Biotechnology industry.

( Industry Median: 116.21 vs. GILD: 178.16 )
Ranked among companies with meaningful Days Inventory only.
GILD' s 10-Year Days Inventory Range
Min: 148.53  Med: 242.48 Max: 405.59
Current: 178.16
148.53
405.59
Days Sales Outstanding 64.21
GILD's Days Sales Outstanding is ranked lower than
52% of the 557 Companies
in the Global Biotechnology industry.

( Industry Median: 61.10 vs. GILD: 64.21 )
Ranked among companies with meaningful Days Sales Outstanding only.
GILD' s 10-Year Days Sales Outstanding Range
Min: 65.89  Med: 74.47 Max: 115.9
Current: 64.21
65.89
115.9

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.37
GILD's Dividend Yield is ranked lower than
87% of the 222 Companies
in the Global Biotechnology industry.

( Industry Median: 1.13 vs. GILD: 0.37 )
Ranked among companies with meaningful Dividend Yield only.
GILD' s 10-Year Dividend Yield Range
Min: 0  Med: 0.00 Max: 0
Current: 0.37
Yield on cost (5-Year) 0.37
GILD's Yield on cost (5-Year) is ranked lower than
88% of the 221 Companies
in the Global Biotechnology industry.

( Industry Median: 1.51 vs. GILD: 0.37 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
GILD' s 10-Year Yield on cost (5-Year) Range
Min: 0  Med: 0.00 Max: 0
Current: 0.37
Share Buyback Rate -1.40
GILD's Share Buyback Rate is ranked higher than
81% of the 493 Companies
in the Global Biotechnology industry.

( Industry Median: -10.70 vs. GILD: -1.40 )
Ranked among companies with meaningful Share Buyback Rate only.
GILD' s 10-Year Share Buyback Rate Range
Min: 6.2  Med: -3.40 Max: -24.5
Current: -1.4

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 33.06
GILD's Price/Tangible Book is ranked lower than
94% of the 683 Companies
in the Global Biotechnology industry.

( Industry Median: 5.78 vs. GILD: 33.06 )
Ranked among companies with meaningful Price/Tangible Book only.
GILD' s 10-Year Price/Tangible Book Range
Min: 2.08  Med: 9.49 Max: 214.73
Current: 33.06
2.08
214.73
Price/Projected FCF 1.93
GILD's Price/Projected FCF is ranked higher than
77% of the 152 Companies
in the Global Biotechnology industry.

( Industry Median: 4.29 vs. GILD: 1.93 )
Ranked among companies with meaningful Price/Projected FCF only.
GILD' s 10-Year Price/Projected FCF Range
Min: 0.77  Med: 2.30 Max: 20.81
Current: 1.93
0.77
20.81
Price/Median PS Value 0.77
GILD's Price/Median PS Value is ranked higher than
74% of the 539 Companies
in the Global Biotechnology industry.

( Industry Median: 1.17 vs. GILD: 0.77 )
Ranked among companies with meaningful Price/Median PS Value only.
GILD' s 10-Year Price/Median PS Value Range
Min: 0.44  Med: 1.37 Max: 5.19
Current: 0.77
0.44
5.19
Price/Peter Lynch Fair Value 0.53
GILD's Price/Peter Lynch Fair Value is ranked higher than
96% of the 50 Companies
in the Global Biotechnology industry.

( Industry Median: 2.11 vs. GILD: 0.53 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
GILD' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.4  Med: 1.08 Max: 9.13
Current: 0.53
0.4
9.13
Price/Graham Number 4.20
GILD's Price/Graham Number is ranked lower than
58% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. GILD: 4.20 )
Ranked among companies with meaningful Price/Graham Number only.
GILD' s 10-Year Price/Graham Number Range
Min: 1.59  Med: 3.48 Max: 15.08
Current: 4.2
1.59
15.08
Earnings Yield (Greenblatt) (%) 10.30
GILD's Earnings Yield (Greenblatt) (%) is ranked higher than
95% of the 816 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. GILD: 10.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GILD' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.2  Med: 5.85 Max: 15
Current: 10.3
0.2
15
Forward Rate of Return (Yacktman) (%) 34.52
GILD's Forward Rate of Return (Yacktman) (%) is ranked higher than
80% of the 87 Companies
in the Global Biotechnology industry.

( Industry Median: 14.58 vs. GILD: 34.52 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
GILD' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 0.4  Med: 3.85 Max: 46.1
Current: 34.52
0.4
46.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, BIIB, CELG, CMXHY » details
Traded in other countries:GIS.Germany, GILD.Chile, GILD.Switzerland, GILD.Mexico,
Gilead Sciences Inc was incorporated in Delaware on June 22, 1987. The Company is a research-based biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors. With each new discovery and experimental drug candidate, it seeks to improve the care of patients suffering from life-threatening diseases around the world. The Company's primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases such as hepatitis B and C and serious cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Australia. It markets products in the HIV/AIDS, liver diseases, respiratory and cardiovascular/metabolic therapeutic areas. The Company's products comprise Truvada is an oral formulation dosed once a day as part of combination therapy to treat human immunodeficiency virus infection in adults. Atripla is an oral formulation dosed once a day for the treatment of HIV infection in adults. Viread is an oral formulation of a nucleotide analogue reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. Emtriva is an oral formulation of a nucleoside analogue reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. Hepsera is an oral formulation of a nucleotide analogue polymerase inhibitor, dosed once a day to treat chronic hepatitis B. AmBisome is a proprietary liposomal formulation of amphotericin B, an antifungal agent to treat serious invasive fungal infections caused by various fungal species. Letairis is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension in patients with WHO Class II or III symptoms to improve exercise capacity and delay clinical worsening. Ranexa is indicated for the treatment of chronic angina. Vistide is an antiviral medication for the treatment of cytomegalovirus retinitis in patients with AIDS. Cayston is an inhaled antibiotic as a treatment to improve respiratory systems in cystic fibrosis patients with Pseudomonas aeruginosa. The Company has U.S. and international commercial sales operations, with marketing subsidiaries in Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, the Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland, Turkey, the United Kingdom and the United States. The Company sells and distributes Truvada, Viread, Emtriva, Hepsera and AmBisome in Asia, Australia, Europe, Latin America, the Middle East and New Zealand either through its commercial teams, third party distributors or corporate partners. The Company's products and development programs target a number of areas, including viral, fungal, respiratory and cardiovascular diseases. The Company's products compete with other available products based mainly on: efficacy; safety; tolerability; acceptance by doctors
» More Articles for GILD

Headlines

Articles On GuruFocus.com
Julian Robertson Discusses Greece Threat, Stocks and Apple Jun 30 2015 
Why I Am Buying Gilead Sciences Jun 30 2015 
Alan Fournier Sells Stake in Gilead Sciences Jun 25 2015 
Weekly 52-Week Highs Highlight: GILD, XL, STJ, NKE Jun 20 2015 
Weekly CFO Sells Highlight: Comcast Corp, Affiliated Managers Group Inc, and Gilead Sciences Inc. Jun 16 2015 
t Jun 11 2015 
gild Jun 02 2015 
Gilead Sciences Pursues Expansion Plans In Canada Jun 02 2015 
COE May 28 2015 
Risk & Reward with Gilead Sciences Inc. (GILD) May 14 2015 

More From Other Websites
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Harvoni®, the First Once-Daily... Jul 03 2015
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Harvoni®, the First Once-Daily... Jul 03 2015
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Harvoni®, the First Once-Daily... Jul 03 2015
Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point Jul 02 2015
Gilead Submits Marketing Application for HIV Drug to FDA - Analyst Blog Jul 02 2015
Juno, Celgene Lead 5 Top Biotechs Nearing Buy Point Jul 01 2015
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Single Tablet Regimen... Jul 01 2015
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Single Tablet Regimen... Jul 01 2015
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Single Tablet Regimen... Jul 01 2015
Is Gilead Just the First Biotech Stock to Sink? Jul 01 2015
Can Hepatitis B Be A Blockbuster Bug? Jul 01 2015
Jim Cramer's Top Takeaways: Celgene, Gilead Sciences, Regeneron, Alarm.com, TransUnion Jul 01 2015
Julian Robertson Really Likes Gilead Sciences Jun 30 2015
Your first trade for Wednesday, July 1 Jun 30 2015
Fast Money Final Trade: GILD, KORS, SPY & KITE Jun 30 2015
Proud Gilead shareholder: Julian Robertson Jun 30 2015
Why is Celgene So Darn Expensive? Jun 30 2015
Is Celgene's Juno Deal a Boon or a Boondoggle? Jun 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK